Combination therapy to treat osteoporosis
CA 2198580 C · Owner: Pfizer Inc. · Inventors: Thompson, David D; Maclean, David B.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a pharmaceutical composition for treating or preventing osteoporosis in a mammal in need of treatment which composition comprises an effective amount of a compound of formula I (see fig.I), wherein, R1 and R2 may be the same or different provided that when R1 and R2 are the same, each is a methyl or ethyl group and , when R1 and R2 are different, one of them is a methyl or ethyl group and the other is hydrogen or a benzyl group; or a pharmaceutically acceptable salt thereof; together with a bone resorption inhibiting polyphosphonate, or with parathyroid hormone.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 26, 1997 and granted July 3, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 26, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 26, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.